Table 1.

Clinicopathologic factors of breast cancer patients in disease-free and progressed statuses.

Dataset was retrieved from our previous study [21]

Factors	Disease-free (n = 84)		Progresseda (n = 21)		P
	n	%	n	%
Tissue visfatin					< 0.001
≤ 50%	51	60.7	4	19.0
> 50%	33	39.3	17	81.0
Stage					< 0.001
I, II	73	86.9	10	47.6
III, IV	11	13.1	11	52.4
Grade					0.669
1, 2	60	71.4	14	66.7
3	24	28.6	7	33.3
Age (years)					0.002
< 50	51	60.7	5	23.8
≥ 50	33	39.3	16	76.2
BMI (kg/m2)					0.195
< 24	53	63.1	10	47.6
≥ 24	31	36.9	11	52.4
Tumor size (cm)					0.007
< 2	44	52.4	4	19.0
≥ 2	40	47.6	17	81.0
LN metastasis					< 0.001
Negative	59	70.2	6	28.6
Positive	25	29.8	15	71.4
ER					0.051
Positive	59	70.2	10	47.6
Negative	25	29.8	11	52.4
PR					0.139
Positive	51	60.7	9	42.9
Negative	33	39.3	12	57.1
HER2 status					0.417
Positive	32	38.1	6	28.6
Negative	52	61.9	15	71.4
Triple negative					0.031
No	70	83.3	13	61.9
Yes	14	16.7	8	38.1
RT					0.487
Yes	51	60.7	11	52.4
No	33	39.3	10	47.6
CT					0.557
Yes	66	78.6	18	85.7
No	18	21.4	3	14.3
HT					< 0.001
Yes	60	71.4	6	28.6
No	24	28.6	15	71.4

BMI body mass index, LN lymph node, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, RT radiotherapy, CT chemotherapy, HT hormone therapy

^aProgressed patients including patients with breast cancer recurrence or patients expired during 5-year follow-up